Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

in response to

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

tada

posted on Jan 30, 2019 10:14AM

Tada,

If that's case i wonder why we have yet to hear any large deal with Zenith, I consider the pfizer trial collaboration to be a very good sign they are interested in a deal with Zenith but not confident enough, to go full ahead yet .... Any deal with Zentih should be larger than than Celgene if we are in a phase 2 trial as you say,

5 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply